Detailed Information

Cited 0 time in webofscience Cited 24 time in scopus
Metadata Downloads

Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disordersopen access

Authors
Zeb, A.Son, M.Yoon, S.Kim, J.H.Park, S.J.Lee, K.W.
Issue Date
2019
Publisher
Elsevier B.V.
Keywords
Cdk5/p25 inhibitors; Molecular docking; Molecular dynamics simulation; Structure-based pharmacophore modeling; Tau-pathogenesis
Citation
Computational and Structural Biotechnology Journal, v.17, pp.579 - 590
Indexed
SCIE
SCOPUS
Journal Title
Computational and Structural Biotechnology Journal
Volume
17
Start Page
579
End Page
590
URI
https://scholarworks.bwise.kr/gnu/handle/sw.gnu/10662
DOI
10.1016/j.csbj.2019.04.010
Abstract
Deregulation of Cdk5 is a hallmark in neurodegenerative diseases and its complex with p25 forms Cdk5/p25, thereby causes severe neuropathological insults. Cdk5/p25 abnormally phosphorylates tau protein, and induces tau-associated neurofibrillary tangles in neurological disorders. Therefore, the pharmacological inhibition of Cdk5/p25 alleviates tau-associated neurological disorders. Herein, computational simulations probed two candidate inhibitors of Cdk5/p25. Structure-based pharmacophore investigated the essential complementary chemical features of ATP-binding site of Cdk5 in complex with roscovitine. Resultant pharmacophore harbored polar interactions with Cys83 and Asp86 residues and non-polar interactions with Ile10, Phe80, and Lys133 residues of Cdk5. The chemical space of selected pharmacophore was comprised of two hydrogen bond donors, one hydrogen bond acceptor, and three hydrophobic features. Decoy test validation of pharmacophore obtained highest Guner-Henry score (0.88) and enrichment factor score (7.23). The screening of natural product drug-like databases by validated pharmacophore retrieved 1126 compounds as candidate inhibitors of Cdk5/p25. The docking of candidate inhibitors filtered 10 molecules with docking score >80.00 and established polar and non-polar interactions with the ATP-binding site residues of Cdk5/p25. Finally, molecular dynamics simulation and binding free energy analyses identified two candidate inhibitors of Cdk5/p25. During 30 ns simulation, the candidate inhibitors established <3.0 ? root mean square deviation and stable hydrogen bond interactions with the ATP-binding site residues of Cdk5/p25. The final candidate inhibitors obtained lowest binding free energies of ?122.18 kJ/mol and ? 117.26 kJ/mol with Cdk5/p25. Overall, we recommend two natural product candidate inhibitors to target the pharmacological inhibition of Cdk5/p25 in tau-associated neurological disorders. ? 2019
Files in This Item
There are no files associated with this item.
Appears in
Collections
자연과학대학 > 화학과 > Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE